Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: yoshimaru y. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, Yoshimaru Y, Tateyama M, Setoyama H, Naoe H, Kikuchi K, Sasaki Y. Fukubayashi K, et al. Among authors: yoshimaru y. Cancer Med. 2015 Aug;4(8):1214-23. doi: 10.1002/cam4.476. Epub 2015 Jun 4. Cancer Med. 2015. PMID: 26044168 Free PMC article.
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
Oya Y, Sugawara Y, Watanabe T, Yoshimaru Y, Honda M, Hashimoto S, Yoshii D, Isono K, Hayashida S, Yamamoto H, Tanaka M, Sasaki Y, Inomata Y. Oya Y, et al. Among authors: yoshimaru y. Biosci Trends. 2017 Jan 16;10(6):496-499. doi: 10.5582/bst.2016.01223. Epub 2016 Dec 18. Biosci Trends. 2017. PMID: 27990005 Free article. Clinical Trial.
Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients.
Tokunaga T, Tanaka M, Tanaka K, Narahara S, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Tateyama M, Naoe H, Sasaki Y, Tanaka Y. Tokunaga T, et al. Among authors: yoshimaru y. Int J Clin Oncol. 2021 May;26(5):922-932. doi: 10.1007/s10147-020-01835-2. Epub 2021 Mar 17. Int J Clin Oncol. 2021. PMID: 33730200
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Narahara S, et al. Among authors: yoshimaru y. Hepatol Commun. 2022 May;6(5):1198-1212. doi: 10.1002/hep4.1872. Epub 2021 Nov 27. Hepatol Commun. 2022. PMID: 34837478 Free PMC article.
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.
Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Nakano M, et al. Among authors: yoshimaru y. Sci Rep. 2022 Jan 27;12(1):1517. doi: 10.1038/s41598-022-05444-z. Sci Rep. 2022. PMID: 35087153 Free PMC article.
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: yoshimaru y. Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568. Cancers (Basel). 2023. PMID: 36900359 Free PMC article.
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Huang DQ, et al. Among authors: yoshimaru y. Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Hepatology. 2023. PMID: 37184202
19 results